

Supplementary Figure S5. Kaplan-Meier analysis of OS in the ITT population and the tTMB BEP. BEP, biomarker-evaluable population; CI, confidence interval; D, durvalumab; EP, platinum-etoposide; HR, hazard ratio; ITT, intention-to-treat; OS, overall survival; T, tremelimumab; tTMB, tissue tumor mutational burden.

